![Kimberly Blackwell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kimberly Blackwell
Directeur Général chez ZENTALIS PHARMACEUTICALS, INC.
Fortune : 2 M $ au 30/06/2024
Profil
Kimberly L.
Blackwell is the founder of Cereius, Inc. (founded in 2017) and holds the title of President.
She is currently the Chief Executive Officer & Director at Zentalis Pharmaceuticals, Inc. (since 2020), Director at Fore Biotherapeutics, Inc. (since 2021), Independent Director at Century Therapeutics, Inc. (since 2021), and Independent Director at Monte Rosa Therapeutics, Inc. (since 2020).
Previously, she held positions as a Director at Neoantigenics, Inc., Director at Century Therapeutics, Inc. (2021), VP-Early Phase Oncology & Immuno-Oncology at Eli Lilly & Co. (2018-2020), and Chief Medical Officer & SVP-Clinical Oncology at Tempus AI, Inc. (2020-2022).
She also served as the Director-Women's Cancer Program & Professor at Duke Cancer Institute (1997-2018) and as a Professor at Duke University (1997-2018).
Dr. Blackwell obtained her undergraduate degree from Duke University and her doctorate degree from Mayo Clinic College of Medicine & Science.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
01/02/2024 | 484 145 ( 0,68% ) | 2 M $ | 30/06/2024 | |
12/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 | |
20/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Kimberly Blackwell
Sociétés | Poste | Début |
---|---|---|
ZENTALIS PHARMACEUTICALS, INC. | Directeur Général | 10/05/2022 |
MONTE ROSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/06/2020 |
CENTURY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/05/2021 |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Directeur/Membre du Conseil | 20/09/2021 |
Cereius, Inc.
![]() Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Fondateur | 01/01/2017 |
Anciens postes connus de Kimberly Blackwell
Sociétés | Poste | Fin |
---|---|---|
Tempus Labs, Inc.
![]() Tempus Labs, Inc. Packaged SoftwareTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Directeur Technique/Scientifique/R&D | 16/05/2022 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/03/2020 |
Duke University
![]() Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/01/2018 |
Duke Cancer Institute
![]() Duke Cancer Institute Hospital/Nursing ManagementHealth Services Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources. | Corporate Officer/Principal | 01/01/2018 |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Kimberly Blackwell
Duke University | Undergraduate Degree |
Mayo Clinic College of Medicine & Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 5 |
---|---|
![]() | Technology Services |
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
CENTURY THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Neoantigenics, Inc.
![]() Neoantigenics, Inc. Medical SpecialtiesHealth Technology Neoantigenics, Inc. developes therapeutic plus diagnostic products. The firm focuses on developing oncology theranostics products, founded on the novel science around oocyte (egg)-associated cancer proteins. The company was founded Brian A. Pollok, John C. Herr and Edward J. Leary in July 2012 and is headquartered in Charlottesville, VA. | Health Technology |
Lilly Oncology
![]() Lilly Oncology Hospital/Nursing ManagementHealth Services Part of Eli Lilly & Co., Lilly Oncology is an American company dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. With over 50 years of experience, Lilly Oncology is committed to building on their heritage and improving the lives of all those affected by cancer worldwide. | Health Services |
Century Therapeutics, Inc. /Old/
![]() Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
Duke Cancer Institute
![]() Duke Cancer Institute Hospital/Nursing ManagementHealth Services Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources. | Health Services |
Fore Biotherapeutics, Inc.
![]() Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
Cereius, Inc.
![]() Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Health Technology |